Experts Discuss the Evolution of CAR T-Cell Therapy in Multiple Myeloma

Join us for a live CME-certified webinar on the use of CAR T-cell therapy in the management of multiple myeloma. You will gain insights from expert faculty on the latest clinical data on approved and investigational CAR T therapies and the how these agents can be safely integrated into clinical practice. Register now!

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


  • Welcome and Introduction
  • Overview of CAR T-Cell Therapy
  • Clinical Data on Approved CAR T-cell Therapies in Multiple Myeloma
  • CAR T-cell Therapies in Development for Multiple Myeloma
  • Panel Discussion
  • Audience Question and Answer Session


Date / Time
Event Details


Jesús G. Berdeja, MD

Director of Multiple Myeloma Research
Sarah Cannon Research Institute
Sarah Cannon Center for Blood Cancer
Tennessee Oncology
Nashville, Tennessee

Sagar Lonial, MD

Professor and Chair 
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in integrating CAR T-cell therapy into treatment plans for patients with hematologic malignancies.

Target Audience
This educational program is intended for hematologists, medical oncologists, and other healthcare professionals who treat patients with hematologic malignancies who are eligible for CAR T-cell therapy.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Discover the similarities and differences among currently available and emerging CAR T-cell therapies in multiple myeloma
  • Identify patients who are likely to benefit from CAR T-cell therapy or are eligible for clinical trial enrollment
  • Integrate into practice clinical trial data on CAR T-cell–based therapies for the treatment of multiple myeloma
  • Manage toxicities associated with CAR T-cell therapy using available guidelines and online clinical resources and tools, and implement strategies to educate patients eligible for this treatment about the potential for these complications


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.